Scintigraphic imaging of adrenal disease

Minerva Endocrinologica

Volumn 33, Issue 3, 2008, Pages 175-191

  Gross, M D ^a   Wong, K K ^a   Rubello, D ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Adrenal cortex; Adrenal medulla; Neuroblastoma; Pheochromocytoma; Positron emission tomography; Tomography, emission computed, single photon

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPAMINE F 18; 6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; BRETYLIUM; FLUORODEOXYGLUCOSE F 18; GUANETHIDINE; IODOCHOLESTEROL I 131; LOW DENSITY LIPOPROTEIN; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; DIAGNOSTIC AGENT; HYDROCORTISONE;

ADRENAL CORTEX; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENAL MEDULLA; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; HYPERCORTISOLISM; INCIDENTAL FINDING; INCIDENTALOMA; MULTIPLE ENDOCRINE NEOPLASIA; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERALDOSTERONISM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CARCINOMA; ADRENAL DISEASE; ADRENAL TUMOR; NEUROFIBROMA; RADIOGRAPHY; RETROPERITONEAL TUMOR; SCINTISCANNING; SECRETION;

ADRENAL GLAND DISEASES; ADRENAL GLAND NEOPLASMS; HUMANS; HYDROCORTISONE; INCIDENTAL FINDINGS; NEUROFIBROMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; RETROPERITONEAL NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58149392637     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Gross MD, Korobkin M, Hussain H, Cho KJ, Bui C. Adrenal gland imaging. Chapter 126. In: Jameson JL, Degroot LJ, editors. Endocrinology, 5th ed. Philadelphia; W.B. Saunders; 2005. p. 2425-53.
2. Sarkar SD, Beierwaltes H, Ice RD, Basmadjian GP, Hetzel KR, Kennedy WP et al. A new and superior adrenal scanning agent, NP-59. J Nucl Med 1975;16:1038-42.
3. Thrall JH, Freitas JE, Beierwaltes WH. Adrenal scintigraphy. J Nucl Med 1978;18:23-41.
4. Shapiro B, Britton KE, Hawkins LA, Edwards CRW. Clinical experience with 75Se-selenomethylnorcholesterol adrenal imaging. Clin Endocrinol 1981;15:19-27. (Pubitemid 11050908)
5. 18F]Fluorobenzoate. Nucl Med Biol 1999;26:131-8.
6. Counsell RE, Ranade VV, Blair RJ, Beierwaltes WH, Weinhold PA. Tumor localizing agents. IX. Radioiodinated cholesterol. Steroids 1970;16:317-28.
7. Gross MD, Valk TW, Swanson DP, Thrall JH, Grekin RJ, Beirewaltes WH. The role of pharmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med 1981;11:128-48.
8. 131I-iodomethyl-19-norcholesterol in Cushing's syndrome. J Nucl Med 1980;2:1069-72.
9. Gross MD, Freitas JE, Swanson DP, Brady T, Beierwaltes WH. The normal dexamethasone suppression adrenal scintiscan. J Nucl Med 1979;20:1131-5.
10. Isaacsohn JL, Lees AM, Lees RS, Strauss HW, Barlai-Kovach M, Moore TJ. Adrenal imaging with technetium-99m-labelled low density lipoproteins. Metabolism 1986;35:364-6.
11. 131I). Jpn J Nucl Med 1976;13:775-9.
12. 131I). Jpn J Nucl Med 1976;13:775-9.
13. Fischer M, Vetter W, Winterg B, Zidek W, Vetter H. Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperlasia. Eur J Nucl Med 1982;7:222-4. (Pubitemid 12113127)
14. Nakajo M, Sakata H, Shirono K, Shimabukuro K, Onohara S, Shinohara S. Application of ACTH stimulation to adrenal imaging with radiocholesterol. Clin Nucl Med 1983;8:112-20. (Pubitemid 13132213)
15. Nakajo M, Nakabeppo Y, Tsuchimochi S. Scintigraphic assessment of therapeutic success in aldosteronomas treated by transcatheter arterial embolization using absolute ethanol. J Nucl Med 1997;38:237-41. (Pubitemid 27061602)
16. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568-80.
17. Gross MD, Avram A, Fig LM, Fanti S, Al-Nahhas A, Rubello D. Positron emission tomography in the diagnostic evaluation of adrenal tumors. Q J Nucl Med Mol Imaging 2007;51:260-71.
18. Beierwaltes WH, Wieland DM, Yu T, Swanson DP, Mosley ST. Adrenal imaging agents: rationale, synthesis, formulation and, metabolism. Semin Nucl Med 1978;8:5-12.
19. 18)F-FDG. J Nucl Med 2004;45:972-9.
20. 11C-metomidate. Eur J Nucl Med Mol Imaging 2004;31:1224-30.
21. 18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 2006;33:669-72.
22. Gross MS, Avram A, Fig LM, Rubello D. Contemporary adrenal scintigraphy. Eur J Nucl Med Mol Imaging 2007;34:547-57.
23. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002;147:13-28.
24. Gross MD, Rubello D, Shapiro B. Is there a future for adrenal scintigraphy? Nucl Med Commun 2002;23:197-202.
25. Gross MD, Valk TW, Freitas JE, Swanson DP, Schteingart DE, Beierwaltes WH. The relationship of adrenal iodomethylnorcholesterol uptake to indices of adrenal cortical function in Cushing's syndrome. J Clin Endocrinol Metab 1981;52:1062-6.
26. Smals AGH, Pieters G, Van Haelst V, Kloppenborg P. Macronodular adrenocortical hyperplasia in long-standing Cushing's disease. J Clin Endocrinol Metab 1984;58:25-31. (Pubitemid 14220512)
27. Fig LM, Gross MD, Shapiro B, Ehrmann DA, Freitas JE, Schteingart DE et al. The localization of abnormal adrenal function in the ACTH-dependent Cushing syndrome. Ann Intern Med 1988;109:547-53.
28. Schteingart DE, Seabold JE, Gross MD, Swanson DP. Iodocholesterol adrenal tissue uptake and imaging in adrenal neoplasms. J Clin Endocrinol Metab 1981;52:1156-61.
29. Pasieka JL, McLeod MK, Thompson NW, Gross MD, Schteingart DE. Adrenal scintigraphy of well-differentiated (functioning) adrenocortical carcinomas: potential surgical pitfalls. Surgery 1992;112:884-90.
30. 11C-metomidate imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003;30:403-10.
31. 11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006;91:1410-4.
32. Conn JW, Cohen EL, Herwing KR. The dexamethasone-modified adrenal scintiscan in hyporeninemic aldosteronism (tumor vs hyperplasia). A comparison with adrenal venography and adrenal venous aldosterone. J Lab Clin Med 1976;88:841-55.
33. Gross MD, Shapiro B, Grekin RJ, Freitas JE, Thompson NW, Beierwaltes WH. The scintigraphic localization of the adrenal glands in primary aldosteronism. Am J Med 1984;77:839-44.
34. Ishimura J, Fukuchi M. High diagnostic accuracy of qualitative adrenal SPECT imaging without dexamethasone suppression in primary aldosteronism. J Nucl Med 1992;33:384.
35. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995;16:460-84.
36. Gross MD, Shapiro B, Francis IR, Glazer GM, Bree RL, Arcomano MA et al. Scintigraphic evaluation of clinically silent adrenal masses. J Nucl Med 1994;35:1145-52.
37. Dwamena BA, Kloos RT, Fendrick AM, Gross MD, Francis IR, Korobkin MT et al. Diagnostic evaluation of the adrenal incidentaloma: decision and cost-effectiveness analysis. J Nucl Med 1998;39:707-12.
38. 131I]6β-Iodomethlynorcholesterol standardized uptake trend in clinically silent monolateral and bilateral adrenocortical incidentalomas. Q J Nucl Med and Mol Imaging 2005;49:287-96.
39. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2001;42:884-92.
40. Maurea S, Caraco C, Klain M, Mainolfi C, Salvatore M. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Q J Nucl Med Mol Imaging 2004;48:188-97.
41. 18F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol 2007;14:468-75.
42. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001;42:1795-9.
43. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006;47:32-7. (Pubitemid 46768509)
44. 18F]Fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006;91:2665-71.
45. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumors? Preliminary results in 13 consecutive patients. Eur J of Endocrinol 2004;150:789-92.
46. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy? J Endocrinol Invest 2004;27:387-99.
47. 18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med 2004;29:300-2.
48. 18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome. Ann Nucl Med 2003;17:403-6. (Pubitemid 37071264)
49. Chong S, Lee KS, Kim HY, Kim YK, Kim BT, Chung MJ et al. Integrated PET/CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics 2006;26:1811-26.
50. Elaini R, Shetty S, Chapman VM, Sahani DV, Boland GW, Sweeny AT et al. Improved detection and characterization of adrenal disease with PET-CT. Radiographics 2007;27:755-67.
51. Lieberman LM, Beierwaltes WH, Varma VM, Weinhold P, Ling R. Labeled dopamine concentration in human adrenal medulla and in neuroblastoma. J Nucl Med 1969;10:93-7.
52. Anderson BG, Beierwaltes WH, Harrison TS, Ansari AN, Buswink AA, Ice RD. Labeled dopamine concentration in pheochromocytomas. J Nud Med 1973;14:781-4.
53. Fowler JS, MacGregor RR, Wolf AP. Radiopharmaceuticals. Halogenated dopamine analogs: synthesis and radiolabeling of 6-iododopamine and tissue distribution studies in animals. J Med Chem 1976;19:356-60.
54. Korn N, Buswink A, Yu T, Carr EA Jr, Carroll M, Counsell RE. A radioiodinated bretylium analog as a potential agent for scanning the adrenal medulla. J Nucl Med 1977;18:87-9. (Pubitemid 8019787)
55. 131I) iodobenzylguanidine. J Nucl Med 1980;21:349-53.
56. 131I) metaiodobenzylguanidine [Concise communication]. J Nucl Med 1981;22:358-64.
57. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
58. 131-I-metaiodobenzylguanidine. Ann Intern Med 1981;94:762-7.
59. 131-metaiodobenzylguanidine (I-MIBG) in man: evaluation by scintigraphy. J Nucl Med 1983;24:672-82. (Pubitemid 13016087)
60. 131I-meta-iodobenzylguaindine (MIBG) adrenal medullary scintigraphy: interventional studies. In: Spencer RP, editor. Interventional nuclear medicine. New York: Grune & Stratton; 1983. p. 451-81.
61. 131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9.
62. 131I-MIBG). Ann NY Acad Sci 2006;1073:465-90.
63. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M et al. Synthesis and preliminary evaluation of (HC) metahydroxyephedrine: a false neurotransmitter agent for heart neuronal imaging. J Nucl Med 1990;31:1328-34.
64. Schwaiger M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD et al. Noninvasive evaluation of the sympathetic nervous system in the human heart by PET. Circulation 1990;82:457-64.
65. Nilsson O, Jakobsen AM, Kolby L, Bernhardt P, Forssell-Aronsson E, Ahlman H. Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann NY Acad Sci 2004;1014:280-3.
66. Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann NY Acad Sci 2004;1018:495-504.
67. Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci 2002;970:159-69. (Pubitemid 35286093)
68. Ruffini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Sem Nucl Med 2006;36:228-47.
69. 111In-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endo Metab 2001;86:685-93.
70. Chen L, Li F, Zhuang H, Jing H, Du Y, Zeng Z. Cardiac pheochromocytomas detected by Tc-99m-Hydrazinonicotinyl-Tyr3-Octreotide (HYNIC-TOC) scintigraphy. Clin Nucl Med 2007;32:182-5.
71. Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V et al. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007;28:359-63.
72. Shapiro B, Gross MD, Shulkin BL. Radioisotope diagnosis and therapy of malignant pheochromocytomas. Trends Endocrinol Metab 2001;12:469-75.
73. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS et al. PET scanning with hydroxyepinephrine: an approach to the localization of pheochromocytoma. J Nucl Med 1992;33:1125-31.
74. Shulkin BL. PET epinephrine studies of pheochromocytoma. J Nucl Med 1995;36:22-3.
75. Lynn MD, Shapiro B, Sisson JC, Swanson DP, Mangner TJ, Wieland DM et al. Portrayal of pheochromocytoma and normal human adrenal medulla by 123I-metaiodobenzylguanidine (123I-MIBG). J Nucl Med 1984;25:436-40. (Pubitemid 14131966)
76. Witteles RM, Kaplan EL, Roizen MF. Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice. Arch Int Med 2000;160:2521-4.
77. 131I-metaiodobenzylguanidine for locating pheochromocytomas. Vol. II. In: Raynaud C, editor. Nuclear medicine and biology. Paris: Pergamon Press; 1982. p. 1265.
78. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlee W, Beierwaltes WH. Malignant pheochromocytoma: clinical, biochemical and scintigraphic characterization. Clin Endocrinol 1984;20:189-203. (Pubitemid 14177191)
79. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 2007;14:587-99.
80. Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci 2006;1073:374-82.
81. Laursen K, Damgaard-Pedersen K. CT for pheochromocytoma diagnosis. AJR Am J Roentgenol 1980;134:277-80.
82. Shapiro B, Sisson J, Kalff V, Glowniak J, Satterlee W, Glazer G et al. The location of middle mediastinal pheochromocytomas. J Thorac Cardiovasc Surg 1984;87:814-20.
83. Timmers HJ, Kozupa A, Chen CC, Carasquillo JA, Ling A, Eisenhofer G et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated peochromocotma and paprganglioma. J Clin Oncol 2007;25:2262-9.
84. Lumachi F, Tregnaghi A, Zucchetta P, Marzola MC, Cecchin D, Grassetto G et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 2006;27:583-7.
85. Guller U, Turek J, Eubanks S, Delong ER, Oertli D, Feldman J. Detecting Pheochromocytoma. Defining the most sensitive test. Ann Surg 2006;243:102-7.
86. Fuertes MJ, Mena GE, Camacho MV, Fructuoso MA, Flotats GA, Estorch CA et al. 123I-MIBG SPECT-CT combined with gamma probe for radioguided localization of pheochromocytoma. Rev Esp Med Nucl 2005;24:418-21.
87. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41.
88. Ilias I, Shulkin B, Pacak K. New functionqal imaging modalities for chromaffin tumors, neuroblastoma and ganglioneuromas. Trends Endocrinol Metab 2005;16:66-72.
89. Trampal C, Engler H, Juhlin C, Bergström M, Långström B. Pheochromocytomas: detection with 11C Hydroxyephedrine PET. Radiology 2004;230:423-8.
90. 131I]-metaiodobenzylguanidine scintography in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003;88:4083-7.
91. 18fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol 2007;157:53-537.
92. 18F-Fluoro-L- DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007;48:1599-606.
93. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005;37:717-21.
94. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med 2004;48:150-63.
95. 18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with Von Hipple-Lindau syndrome. Eur J Endocrinol 2007;156:483-7.
96. Kalff V, Shapiro B, Lloyd R, Sisson JC, Holland K, Nakajo M et al. The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch Intern Med 1982;142:2092-7.
97. Shulkin BL, Shapiro B. Radioiodinated meta-iodobenzylguanidine in the management of neuroblastoma. In: Pochedly C, editor. Neuroblastoma. Boca Raton, FL: CRC Press; 1990. p. 171-98.
98. Gelfand MJ. Metaiodobenzylguanidine in children. Semin Nucl Med 1993;23:231-42.
99. Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, Pritchard J. Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-MIBG scans. J Nucl Med 1990;31:129-34. (Pubitemid 20059210)
100. 131I-MIBG and bone scintigraphy for the detection of neuroblastoma. J Nucl Med 1992;33:1735-40.
101. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG et al. Castle VP. Sisson JC. Hutchinson RJ. PET hydroxyephedrine imaging of neuroblastoma J Nucl Med 1990;37:16-21.